Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Africa: When Ebola Strikes, HIV Care Cannot Stop

[Africa CDC] As the Democratic Republic of the Congo responds to the Ebola outbreak in Ituri, there are growing concerns about people living with HIV missing their regular care and treatment.

The Democratic Republic of the Congo is currently facing a growing concern as the Ebola outbreak in Ituri spreads. With fear, insecurity, and pressure on health services, people living with HIV are finding it increasingly difficult to access their regular care and treatment. Missing their medicines can quickly deteriorate their health. Therefore, the Ebola response must prioritize the protection of essential health services, including HIV care, to ensure that these vital services are not neglected during the outbreak.

Community organizations and networks of people living with HIV are playing a crucial role in this situation. They are working tirelessly to locate patients who have stopped attending clinics, reconnect them with care, provide necessary medicines, and share trusted information with their communities. This experience highlights the importance of integrating outbreak response with essential health services. It demonstrates that patients require care for all their health needs, even during emergencies.

Maintaining HIV services, supporting community organizations, and ensuring safe patient movement between services are critical factors in saving lives and strengthening health systems. AllAfrica, a news agency, reports that these issues must be addressed concurrently to effectively combat the Ebola outbreak and build resilient health systems. For more information, read the full article on Health Policy Watch.

Written by urgent.news from AllAfrica Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 1 other outlet

Read the original at allafrica.com →

More in Health & Medicine

Innovent Biologics expands Phase 3 lung cancer trial globally

Biopharmaceutical manufacturer Innovent Biologics expanded its global Phase 3 MarsLight 11 clinical trial of candidate IBI363 TAK 928 to evaluate patients with immunotherapy resistant non squamous non…

  • Innovent Biologics expands MarsLight-11 Phase 3 lung cancer trial globally.
  • Trial now includes non-squamous non-small cell lung cancer patients.
  • IBI363/TAK-928 bispecific fusion protein assessed against docetaxel.

More from Monday 28 September →